Rebecca M. Nisbet

This study develops a polyanionic peptibody, ACR12, that reduces tau aggregation and restores neuronal protein levels in a tau transgenic mouse model.

This study shows that a novel Tau antibody, RNJ1, restores proteostasis in a tauopathy model by reducing pathological Tau and normalizing protein and phosphoprotein levels.

This study demonstrates that synthetic mRNA encoding anti-Tau monoclonal antibodies and scFv intrabodies can be translated into functional antibodies in SH-SY5Y cells.

This study shows that APOE4 increases tau levels in brain endothelial cells, reducing anti-tau antibody delivery across the blood-brain barrier in vitro.

This study evaluates whether ultrasound-mediated delivery of a tau-specific monoclonal antibody improves therapeutic efficacy in a tauopathy model, finding increased brain uptake but no additive therapeutic benefit.

This study demonstrates that focused ultrasound with microbubbles enhances the delivery of Aducanumab and anti-Tau antibodies across a human sporadic Alzheimer's disease blood-brain barrier model.